Branched-Chain Amino Acids (BCAA) Supplementation: Participants will receive oral branched-chain amino acids (BCAA), including leucine, isoleucine, and valine, as a dietary supplement in addition to standard spectacle correction. The intervention is administered daily for approximately 6 months. The supplement is a commercially available nutritional product obtained via cross-border e-commerce channels and is not intended as a therapeutic drug. The aim is to evaluate the effect of BCAA supplementation on myopia progression and ocular biometric parameters.
Study summary
This study is a randomized controlled trial designed to evaluate whether branched-chain amino acid (BCAA) supplementation can help slow the progression of myopia in young adults.
Eligible participants will be randomly assigned to receive either BCAA supplementation combined with standard spectacle correction or standard spectacle correction with a matching placebo. The intervention period will last approximately six months.
Participants will undergo regular follow-up examinations, including measurements of visual acuity, refractive error, axial length, intraocular pressure, and other ocular parameters. Additional assessments such as ocular imaging (including OCTA), physical examinations, and blood tests will also be performed to evaluate eye health and metabolic indicators.
The main purpose of this study is to investigate whether BCAA supplementation can provide a safe and effective nutritional strategy to slow myopia progression and improve understanding of the relationship between amino acid metabolism and ocular growth.
Eligibility
Sex
ALL
Min age
18 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Healthy university students aged 18-25 years;
2. Spherical equivalent refraction (for eyes without prior corneal refractive surgery): SE ≤ -0.50 D;
3. Corrected visual acuity ≥ 0.8;
4. Corneal curvature 40 D-46 D;
5. Good compliance and ability to cooperate with follow-up and examinations;
6. Willingness and ability to participate in this study and sign the informed consent form.
Exclusion Criteria:
1. Strabismus, amblyopia, or other pathological ocular changes;
2. Systemic diseases affecting refractive development and allergic constitution, such as diabetes, metabolic syndrome, etc.;
3. Active eye disease or history of ophthalmic surgery;
4. Use of orthokeratology lenses or other myopia-control interventions within the past 6 months;
5. Use of BCAA-related supplements within the past 6 months, or serum BCAA levels outside the reference range;
6. Considered by the responsible physician to be unable to participate or unable to comply with the study requirements;
7. Abnormal liver or kidney function.
Primary outcome measure(s)
Change in axial length — Baseline to 6 months Axial length (AL) will be measured in both eyes using optical biometry at baseline, 3 months, and 6 months. The primary outcome is the change in axial length from baseline to 6 months, comparing the BCAA supplementation plus spectacle correction group with the spectacle correction only group.
Change in spherical equivalent refractive error — Baseline to 6 months Cycloplegic spherical equivalent (SE) will be measured using autorefractometry under cycloplegia at baseline, 3 months, and 6 months. The primary outcome is the change in spherical equivalent refractive error from baseline to 6 months, comparing the BCAA supplementation group with the control group.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.